Cancer
New treatment for leukaemia nullifies cancer cells
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boston, Cancer, Germany, Harvard, Mainz University, leukaemia
New research was able to demonstrate that a targeted drug-based inactivation of two chromatin regulators would interrupt the self-renewal of …
Transgene announce key partnership with Merck KGaA and Pfizer
October 12, 2016Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck
Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …
Takeda enters $790m cancer development deal
October 11, 2016Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody
Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …
Kite Pharma flying high after promising Car-T trial
September 27, 2016Manufacturing and Production, Research and Development Cancer, Cart-T, kite pharma
Cart-T cell drugs are made by genetically altering patients’ T-cells to add a component of antibodies that make them better …
Untested cancer drug suspected cause of three deaths at German alternative medicine centre
August 17, 2016Research and Development 3-Bromopyruvate, Cancer, Germany, alternative medicine, patient deaths
The deaths of three patients at an alternative medicine clinic in Germany have prompted suspicion of a clinically untested cancer …
GSK, Roche and Novo back $86 million immuno-oncology startup
August 17, 2016Research and Development CD47, Cancer, GSK, Novo, Roche, Tioma, oncology
Brisbane-based venture-stage biopharmaceutical company Tioma Therapeutics has announced it has raised $86 million in Series A venture financing for its …
FDA approves MSD’s Keytruda for head and neck cancer treatment
August 8, 2016Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda
The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …
New drugs to utilise DNA damage response to kill cancer cells
July 26, 2016Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex
The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …
Coherus BioSciences says Neulasta biosimilar shows positive topline results; shares jump
July 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Coherus BioSciences, biosimilar, drug trial
Shares in Coherus BioSciences (Nasdaq: CHRS) jumped to close over 27% after the company said its biosimilar copy for Amgen’s …
Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund
July 7, 2016Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif
The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …
Eisai launches cancer drug Lenvatinib in Mexico
July 4, 2016Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch
Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …
Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer
July 4, 2016Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study
Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …
Novartis signs $150 million deal with Xencor to develop bispecific antibodies
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial
Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …
Takeda to return molecules/ products for Japan to Amgen
June 27, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Japan, Takeda Pharmaceutical, drug development, drug trial
Japanese firm Takeda Pharmaceutical (TSE: 4502) said it will return the rights to develop and market multiple molecules/ products from …
Novartis’ Afinitor gets EU approval to treat cancerous gastrointestinal or lung tumors
June 2, 2016Research and Development, Sales and Marketing Afinitor, Cancer, European Commission, Novartis, regulation
Swiss drugmaker Novartis (VTX: NOVN) on Thursday said the European Commission has approved its Afinitor (everolimus) to treat cancerous gastrointestinal …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
